General Biotechnology

Patent expiry is no longer just a legal milestoneits a commercial strategy.
For payers, the question isnt simply when exclusivity ends. Its what happens nextand how quickly you can turn that moment into measurable value for patients and budgets. In a…

Drug patents are breakingand personalized medicine is the stress test.
For years, the patent system has been treated like a sturdy bridge: predictable timelines, clear incentives, and a steady flow of revenue that funds the next wave of R&D. But th…

Pharma doesnt lose to competitors because it lacks data.
It loses because it cant turn data into decisions fast enough.
Thats the uncomfortable truth behind the market researcher modelan approach built for broad narratives, delayed reporting cycles, an…

Most teams dont lose because theyre outmatchedthey lose because theyre blind.
In pharma, blind usually means youre watching competitors only after theyve already made their moves: a press release, a trial update, a conference poster, a new label expans…

AI-Discovered Drugs Are Here. The Patent Ownership Fight Is Already Underway.
The next era of pharma wont be defined by who can generate the best moleculeitll be defined by who can own the rights to it.
Thats the uncomfortable truth behind the growing …

Rare diseases dont just demand sciencethey demand strategy. And for patent challengers, the playbook that worked in more standard markets often fails when the stakes are higher, the timelines are tighter, and the evidence is messier.
Heres the agitatio…

Cannabinoid Gold Rush Is RealBut the Winners Arent the Loudest Investors. Theyre the IP Operators.
The cannabis industry loves to talk about cultivation, brands, and clinical promise. But the next phase of value creation in cannabinoids wont be decided…

Pharma has spent decades building moats around moleculescomposition-of-matter, method-of-use, manufacturing know-how. But the IP frontier is shifting, and diagnostic patents are now where the next wave of leverage is being quietly assembled.
Heres the …

The Platform Technology Moat: Why the Single-Molecule Patent No Longer Wins the IP War
In pharma, the old playbook used to be simple: find a blockbuster molecule, secure a strong patent around it, and ride the exclusivity wave for years. But the IP war…

The supply chain tells the story before the market does. Heres how to read it.
Most people wait for the headline: Generic launches.
But by the time a generic hits the shelf, the real workmanufacturing, regulatory readiness, logistics, and commercial ti…